

ASPC 2025 CONGRESS ON CVD PREVENTION SCIENTIFIC SESSIONS AGENDA

Dates and times subject to change

FRIDAY, AUGUST 1, 2025

SESSION	NAME OF SESSION	SPEAKER/MODERATOR
Session 1	Opening Session & Award Lectures	
8:00 – 8:20 AM	Welcome Remarks & President's Address	Michael Shapiro, DO, MCR, FASPC
8:20 – 8:35 AM	Honorary Fellow Award Lecture	Helen Hobbs, MD
8:35 – 8:50 AM	Joseph Stokes III, MD Pioneer in Prevention Award Lecture	Roger Blumenthal, MD, FASPC
8:50 – 9:05 AM	Nanette Wenger Award Lecture	Harmony Reynolds, MD
9:05 – 9:20 AM	American Journal of Preventive Cardiology Editors' Update	Erin Michos, MD, MHS, FASPC
Session 2	Bridging Populations and Prevention: How Prospective Cohorts Have Informed Prevention of CVD	
9:20 – 9:35 AM	Lessons from Framingham	Matthew Nayor, MD, MPH
9:35 – 9:50 AM	Lessons from Bogalusa	Keith Ferdinand, MD, FASPC
9:50 — 10:05 AM	Lessons from Women's Health Initiative	JoAnn Manson, MD, MPH, DrPH
10:05 – 10:25 AM	Q & A	
10:25 – 11:00 AM	Networking Break	
Session 3	EAS/ASPC Joint Session – Advances in Lipoprotein(a) Management: Transatlantic Insights	
11:00 – 11:15 AM	Genetics and Pathophysiology of Lipoprotein(a): New Insights	Florian Kronenberg, MD
11:15 – 11:30 AM	Integrating Lipoprotein(a) into Risk Assessment and Management: European vs. American Guidelines	Prof. Dr. Lale Tokgözoğlu
11:30 – 11:45 AM	Lipoprotein(a): Myths, Misconceptions, and Management	Michael Shapiro, DO, MCR, FASPC
11:45 АМ — 12:00 РМ	Emerging Therapies for Lowering Lipoprotein(a): Clinical Trial Updates	Harpreet Bhatia, MD, MAS, FASPC
12:00 — 12:15 РМ	Q & A	
12:30 — 1:15 РМ	Expert Theater Lunch Presentations	



Session 4	Debates in Preventive Cardiology – Round 1	
1:30 - 2:00 PM	The Systolic Blood Pressure Goal Should Be <120 mmHg, Not <130	Paul Whelton, MD, MSc (Pro) vs. Raymond Townsend, MD (Con)
2:00 — 2:30 РМ	Colchicine Should Be Recommended for Secondary Prevention of Coronary Disease	Paul Ridker, MD, MPH (Pro) vs. Sanjit Jolly, MD, MSc (Con)
2:30 — 3:00 РМ	ApoB Measurement Should Replace LDL-Cholesterol	Ann Marie Navar, MD, PhD, FASPC (Pro) vs. Roger Blumenthal, MD, FASPC (Con)
3:00 — 3:30 РМ	Q & A	
3:30 – 4:00 PM	Networking Break	
Session 5	Artificial Intelligence and Technology in the Practice of Preventive Cardiology	
4:00 – 4:15 PM	Al Language Models in Preventive Cardiology: Hope, Hype & Dr. ChatGPT	Ashish Sarraju, MD
4:15 – 4:30 РМ	Opportunistic and Inclusive Prevention: Al and Health Techquity	Fatima Rodriguez, MD, MPH, FASPC
4:30 – 4:45 PM	Wearables and Mobile Health Technologies for Preventive Cardiology Solutions	Seth Martin, MD, MHS, FASPC
4:45 – 5:00 PM	Development to Deployment of Cardiovascular Al	Pierre Elias, MD
5:00 – 5:20 PM	Q & A	
5:20 - 5:30 PM	Annual ASPC Business Meeting	
5:30 - 6:30 PM	Networking Break / Oral Abstract Presentations	
6:30 — 7:30 РМ	Welcome Reception	
7:30 — 9:30 РМ	Dinner Symposium	

Saturday, August 2, 2025

Session	Name of Session	Speaker / Moderator
8:00 – 8:45 AM	Expert Theater Breakfast Presentations	
8:55 – 9:00 AM	Day 2 Welcome	
Session 6	Discussions and Debates in Preventive Cardiology	
The Best Way to Assess Risk in YOUNG Adults		
9:00 – 9:10 AM	Risk Factors	Sadiya Khan, MD, MSc
9:10 – 9:20 AM	Polygenic Risk Score	Pradeep Natarajan, MD, MMSC
9:20 – 9:30 AM	Imaging	Ron Blankstein, MD, FASPC



9:30 – 10:00 AM	Hormone Therapy Should Be Used for Prevention of ASCVD	Leslie Cho, MD (Pro) vs. Martha Gulati, MD, MS, MASPC (con)
10:00 — 10:30 АМ	Serial Anatomic Imaging is the Best Way to Monitor Response to Therapy for Patients with Atherosclerosis	David Maron, MD, FASPC vs. Matthew Budoff, MD, FASPC
10:30 — 10:45 АМ	Q & A	
10:45 – 11:15 AM	Networking Break	
Session 7	Early Career Research Presentations	Larry Sperling, MD, MASPC
11:15 AM — 12:05 PM	Early Career Research Presentations	Spencer Carter, MD Matthew Shotwell, MD Brooke Zlotshewer, MD
12:15 – 1:00 PM	Expert Theater Lunch Presentations	
Session 8	Career Phenotypes in Preventive Cardiology	
1:15 – 1:30 РМ	Clinical Research	Khurram Nasir, MD, MPH, FASPC
1:30 – 1:45 PM	Private Practice	Danielle Belardo, MD, FASPC
1:45 — 2:00 РМ	Cardiovascular Imaging	Ron Blankstein, MD, FASPC
2:00 – 2:15 PM	Industry	Sergio Fazio, MD, PhD, FASPC
2:15 – 2:30 PM	Q & A	
Session 9	Expanding the Scope: Prevention of Heart Failure and Atrial Fibrillation	
2:30 – 2:35 PM	Patient with Atrial Fibrillation	Joe Dolan
2:35 – 2:50 PM	Prevention of Atrial Fibrillation	Christine Albert, MD, MPH
2:50 – 2:55 PM	Patient with Heart Failure	TBD
2:55 – 3:10 PM	Prevention of Heart Failure	Clyde Yancy, MD, MSc
3:10 — 3:30 РМ	Q&A	
3:30 – 4:00 PM	Networking Break	
Session 10	Case Presentations with Expert Faculty Panel	David Maron, MD, FASPC (Moderator)
4:00 – 4:10 PM	Case 1: CAC score >1000, no Sx Presented by: Arthur Shiyovich	Expert Panel: Shoa Clarke. MD, PhD Fatima Rodriguez, MD, MPH, FASPC Ashish Sarraju, MD Garima Sharma, MD
4:10 – 4:25 PM	Discussion	
4:25 – 4:35 PM	Case 2: 3VD, No Sx Presented by: Alexandra Smith	
4:35 – 4:50 PM	Discussion	



4:50 – 5:00 PM	Case 3: Lipid management in pregnancy/breast feeding Presented by: Amanda Jowell	
5:00 – 5:15	Discussion	
5:15 — 5:20 РМ	Early Career Research Winner Announcement	
5:20 — 7:00 РМ	Networking Break / Oral Abstract Presentations	
6:30 — 7:30 РМ	Abstract Author Reception	
7:30 – 9:30 PM	Dinner Symposium	

Sunday, August 3, 2025

Session	Name of Session	Speaker / Moderator
Breakfast Symposium	Assessing Women's Cardiovascular Risk Across the Lifespan	Alison Bailey, MD, FASPC
8:30 – 8:40 AM	Preconception Prevention Planning	Kardie Tobb, DO
8:40 — 8:50 AM	The Role of Prevention During & After Reproduction	ljeoma Isiadinso, MD, MPH
8:50 — 9:00 AM	Menopause & CV Risk	Lily N. Dastmalchi, DO, MA
9:00 – 9:10 AM	The Role of Prevention in the Aging Geriatric Woman	Anne Marie Kerchberger, MD
9:10 – 9:20 AM	Assessing Cardiovascular Risk in Women Throughout the Lifespan	Martha Gulati, MD, MS, MASPC
9:20 – 9:30 AM	Panel Discussion	Alison Bailey, MD, FASPC
9:35 – 9:40 AM	Day 3 Welcome	
Session 11	Sunday Keynote Address	
9:40 — 10:00 AM	Universal Screening for LDL, CRP, and Lp(a)	Paul Ridker, MD, MPH
Session 12	Exploring the Impact of GLP-1 Receptor Agonists	
10:00 — 10:15 АМ	Understanding GLP-1 Receptor Agonists: Mechanisms and Clinical Outcomes	Jorge Plutzky, MD
10:15 — 10:30 АМ	The Heart of the Matter: GLP-1 Receptor Agonists and Cardiovascular Outcomes	TBD
10:30 — 10:45 АМ	The Next Frontier: Innovations and Future Research in GLP-1 Agonist Therapy	Christos Mantzoros, MD, DSc, PhD
10:45 — 11:00 АМ	Who, When, and How: Guidelines for the Use of GLP-1 Receptor Agonists	Darren McGuire, MD, MHSc
11:00 – 11:15 AM	Q & A	
11:15 – 11:30 AM	Networking Break	



Session 13	Hypertension	
11:30 — 11:45 АМ	Underrecognized, Undertreated, and Underappreciated	Karol Watson, MD, PhD, FASPC
11:45 АМ — 12:00 РМ	Lifestyle Interventions	Alison Bailey, MD, FASPC
12:00 – 12:15 РМ	Novel Drug Therapy	Luke Laffin, MD
12:15 – 12:30 РМ	Renal Denervation	Deepak Bhatt, MD, MPH
12:30 — 12:45 РМ	Q & A	
12:45 — 1:00 РМ	Closing Remarks & 2026 Announcement	